Spin-off companies

Establishing direct spin-offs from research centers is an important transfer channel. These spin-offs are based on technologies and insights developed by scientists over the course of many years of outstanding research. Not only are these new services, products, and processes able to significantly improve the ones that currently exist, or make them more cost-effective, they also offer first-time solutions for pressing challenges.

Since 2005, over 175 spin-offs from the Helmholtz Association have been founded. Two thirds of them were funded by the Helmholtz Enterprise Program.

Batch I/2018

Osteolabs has developed an innovative method for diagnostic early diagnosis as well as therapy control of diagnosed osteoporosis. Clinically tested non-invasive calcium isotope biomarkers are used for the B2B and B2C markets.

Neoficient has developed an indoor volume measurement system that can quickly and inexpensively create energetic building models. The automated creation of energy-efficient building models enable efficient energy assessment and documentation of buildings for customers in the fields of energy consulting, public utilities and large property management.


MyoPax Biobank offers patients of all ages, with progressive muscle atrophy, the opportunity to preserve their own stem cells for future individualized treatment of muscle diseases and defects. The Biobank for muscular cell therapy is the precursor to a promising therapy that is currently being developed at the MDC and is expected to become available within a few years.

Theraselect uses the so-called MALDI imaging method to localize a variety of molecules without labeling in clinical and preclinical tissue sections. Drug studies can thus be used to differentiate between active substances and their metabolites (metabolites) by image analysis in order to demonstrate the success of an application. Likewise, for personalized tumor diagnostics, extensive, specific biomarker profiles can be recorded. The MALDI Imaging Analysis outperforms the previous (immune) histological or molecular procedures in terms of speed, cost-efficiency, reliability and objectivity.

FCPP (Fuel Cell Power Pack) develops, assembles and sells fuel cell systems for use in cargo bikes and small electric vehicles, especially for urban last-mile transport. FCPP also implements business model design based on various last-mile logistics concepts for customers.

Simutence develops an improved simulation method for the virtual product development of fiber reinforced plastics (FRP) in the context of services and add-on modules. The role of FRP has a high potential for lightweight construction in vehicle structures due to their high stiffness and low weight. Based on the prediction of manufacturing effects within a virtual process chain, the simulation software enables the first meaningful and reliable modeling of digital twins of fiber-reinforced plastics.

Heisenberg develops quantum algorithms for the prediction of molecular properties for the chemical and pharmaceutical industries. The Heisenberg software can be used on conventional computers as well as on existing and future quantum computers. Thus, development processes can be accelerated with customers today and the understanding of chemical and physical relationships can be increased. As a result, new processes and products can be realized faster. Heisenberg already enables its customers to benefit from the possibilities of quantum computers in the research and development of materials and medicines and to minimize the risks of changes.

Batch II/2017

CEN-Mat produces highly-specialized custom-made nanomaterials with specific control of the properties of the material. Using a new cost-efficient and eco-friendly synthesis route, the company produces tailor-made materials for customers in the energy, automotive, and pharmaceutical sectors.

µyPrint is marketing a new kind of molecular printer which produces precisely-defined, high-resolution surface patterns for applications in biomedical research and clinical diagnostics at research institutes; customers in industry will be targeted at a later stage.

Eximmium distributes antibodies to manufacturers of biopharmaceuticals, which are produced using a platform technology it has specifically developed based on extracellular vesicles. The new technology enables the identification of previously unknown tumor antigens and simultaneously generates antibodies for these.

DcubeRoc develops and distributes software modules that can simulate the complex processes that occur in underground networks of cracks as realistically as possible for a wide range of geological applications. This technology can be used by government authorities, energy or mining companies involved in the exploitation of geothermal energy or in the final disposal of radioactive material.

Batch I/2017

With its Kinfinity data glove, Kinfinity Solutions turns the human hand into an interactive input device, giving access, on the one hand, to new applications in the fields of virtual reality and augmented reality. On the other hand, it can be used to specify complex movements for robot arms that are connected to it, without requiring any programing.

VECTOR21 develops and distributes market simulation software for the strategy departments of companies and consultancies. In contrast to alternative software products, the scenarios (for example for the diffusion of alternative technologies in the vehicle market) are interactive and live. The user simply accesses input data charts and the software calculates the result within seconds even in the case of complex analyses.

Batch II/2016

Industry 4.0 requires and necessitates the use of robotic systems that have no protective fencing to ensure safe human-robot collaboration (HRC). Moving robot tools and components are potentially extremely hazardous to people. COBOTECT offers a safety module which rapidly encloses robot tools and components in an airbag and then releases them again.


mSquare has developed a new generation of heated repair pads to fix components made of fiber-reinforced plastics such as those used in the wind power, aviation, and automotive industries. Compared to previous solutions, the material properties of the repaired components are significantly improved, while the time needed for their repair is also considerably shorter.


Batch I/2016

dermaSight is developing a mesoscopic device based on an imaging technique for dermatological and endoscopic applications. It uses what is known as “ultra-broadband optoacoustic mesoscopy” to produce high-resolution 3D images. Molecular and physiological parameters can thus be measured in real time and diagnoses can be made much more rapidly.

Until now, the mining and resources industries have had to undertake expensive expeditions and test borings in order to develop new deposits of rare earths or metals. ReSens+ is able to use the algorithms developed in-house using satellites or aerial photographs to rapidly determine the exact location, quality, and quantity of natural resources over an extensive area.

Erzlabor has refined a procedure for mineral analysis, which enables resource-efficient treatment and processing strategies in the fields of exploiting or recycling raw materials. The procedure of automated minerology leads to a reduction in process and production costs due to the increased speed of analysis and the improved quality of output.


Is It Fresh has developed printable sensors based on a new kind of ink technology, which almost makes the currently much-discussed expiry dates on foodstuffs superfluous. This technology allows data to be produced about the freshness status of each food product.

The sFIDA technology developed by scientists at the Forschungszentrum Jülich research center can quantify oligomers (which are co-responsible, for example, for the development and progression of Alzheimer’s Disease (AD)) in an ultrasensitive and specific manner. Furthermore, the technology can be used for other protein conformational disorders such as Parkinson’s Disease. It is initially being offered as a product for diagnostic services to customers in the pharmaceutical industry and in academic research.

The Forschungszentrum Jülich research center has developed a completely new type of drug candidate for treating Alzheimer’s Disease (AD). Both the safety of the drug in treatment and its effectiveness in delaying the progression of the disease in animal models have been demonstrated. This potential active ingredient has a unique mode of action, which targets toxic Aβ peptide oligomers in a direct and specific way. Furthermore, the drug candidate is relatively inexpensive to produce and can be administered orally.

Print Version


    • N. N.
    • Head of Department Transfer and Innovation
      Helmholtz Association
    • Dr. Martin Kamprath
    • Program Manager Transfer and Innovation
      Helmholtz Association